ZIOPHARM Oncology, Inc.
1180 Avenue of the Americas
333 articles with ZIOPHARM Oncology, Inc.
Ziopharm Oncology, Inc., a clinical-stage cellular therapy company focused on hematologic and solid tumor cancers, announced that Company management will participate in two upcoming investor conferences
Ziopharm Oncology Reinforces Clear and Bold Vision for Delivering Value at Annual Shareholders Meeting
Ziopharm Oncology, Inc., held its annual shareholders meeting and reinforced its plan and vision for the Company developed and endorsed by the Board and management team.
Ziopharm Oncology, Inc., announced its financial results for the first quarter ended March 31, 2021 and provided additional corporate updates.
Ziopharm Oncology Scientific Advisor Laurence Cooper, MD, PhD, to Present at University of Pennsylvania Cellicon Valley ’21 Two-Day Live Virtual Educational Symposium
Panel Discussion and Presentation part of Future of Cell and Gene Therapies Event
Ziopharm Oncology to Report First Quarter Financial Results on May 6, 2021Annual shareholder meeting to be held on May 19, 2021
Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the financial markets close, and host its annual shareholder meeting on May 19, 2021
Ziopharm Oncology Scientific Advisor Laurence J. N. Cooper, PhD, MD, Presented Today at Aldevron’s Virtual Breakthrough Speakers SeriesPresentation Highlights Ziopharm’s Suite of Cellular Therapy Technologies
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that Laurence J.N. Cooper, PhD, MD, Scientific Advisor to the Company, was the inaugural presenter at Aldevron’s Virtual Breakthrough Speaker Series.
Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (“RPM”) CAR-T Phase I Trial, being conducted by Eden BioCell, its joint venture with TriArm Therapeutics.
Ziopharm Oncology to Present Poster at American Association for Cancer Research Virtual 2021 Annual MeetingAdds to growing body of published research supporting the development of non-viral TCR-T therapies for the treatment of epithelial cancers
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today it will be presenting a poster at the upcoming American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting.
Chimeric antigen receptor (CAR-T) therapy is one of the biggest cancer therapy breakthroughs of our time, but as with any precise science, there is still some fine-tuning to be done to overcome safety risks, limited payload capacity, and the prohibitive cost of manufacturing.
Ziopharm Oncology Provides Leadership and Corporate Updates; Reports Fourth Quarter and Full Year 2020 Financial Results
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced its financial results for the fourth quarter and year ended December 31, 2020 and provided several additional corporate updates.
Ziopharm Oncology to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast on February 25, 2021Company to Hold R&D Day on Thursday, March 11, 2021
Ziopharm Oncology, Inc. (the “Company”) (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast to discuss financial results for the fourth quarter and full year 2020 on Thursday, February 25, 2021 at 4:30pm EDT. The live call can be accessed by dialing 1-877-451-6152 (U.S. and Canada) or 1-201-389-0879 (International). The passcode for the conference call is 13715482. The live webcast may be accessed using the link here
1/15/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers.
– Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation – – Heidi Hagen elected Lead Independent Director –
Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference and will deliver a corporate overview at the 39 th Annual J.P. Morgan Healthcare Conference. H.C. Wainwright Bioconnect 2021 Conference Date: Monday, January 11, 2021 Time: 6:00 am ET (acc
Ziopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and Lymphomas
– Advances Eden BioCell’s clinical program to validate Rapid Personalized Manufacturing (RPM) – – Clinical trial to study autologous CD19-specific CAR-T using RPM technology designed to reduce cost and simplify production for infusion the day after gene transfer –
Ziopharm Comments on Consent Solicitation ResultsJaime Vieser and Holger Weis Elected to Board of Directors
Ziopharm Oncology , Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, “WaterMill”). Based on the consents received by the Company, Jaime Vieser and Holger Weis have been formally elected to the Ziopharm Board of Directors (the “Board”), while
Ziopharm Oncology , Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced that Satyavrat “Sath” Shukla, CFA, Chief Financial Officer, has informed the Company of his intention to step down from the role effective December 31, 2020 to pursue another opportunity. The Company has initiated a search for a new Chief Financial Officer. Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, said, “On behalf of everyone at Ziopharm,
Ziopharm Oncology, Inc., issued a statement in connection with the consent solicitation initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals following the delay of the original December 11 deadline set by WaterMill for Ziopharm shareholders to deliver written consents in support of the Consent Solicitation.
Ziopharm Continues to Recommend that Shareholders Support Company’s Strong Progress by Returning the GREEN Consent Revocation Card
Has Held Several Discussions with WaterMill to Reach an Amicable Resolution to Consent Solicitation Board Accepts Resignation of Director Elan Ezickson Reiterates Concerns About Professional Past of WaterMill Nominee Holger Weis